NRx Pharmaceuticals increases ATM offering to $4.85M after $1M already sold

NRX Pharmaceuticals, Inc.

Maximum aggregate offering price raised to $4,852,909 under existing August 2023 ATM agreement with H.C. Wainwright.
Prior to this filing, $1.0 million in common stock had been sold under the same agreement.
Prospectus supplement filed April 15, 2024 to register the additional shares.
No specific use of proceeds disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.